|Lamivudine||nucleoside reverse transcriptase inhibitor|
|Nevirapine||non-nucleoside reverse transcriptase inhibitor|
|Zidovudine||nucleoside reverse transcriptase inhibitor|
|Trade names||Duovir-N, Zidovex-LN, others|
Lamivudine/nevirapine/zidovudine (3TC/NVP/AZT) is a medication used to treat HIV/AIDS. It is a fixed dose combination of lamivudine, nevirapine, and zidovudine. It is either used by itself or along with other antiretrovirals. It is a recommended treatment in those who are pregnant. It is taken by mouth twice a day.
The medication is generally well tolerated. Side effects are those of the underlying medications. This includes rash, pancreatitis, low white blood cell levels, and muscle pain. Use is not recommended in those with significant liver problems. Use in pregnancy and breastfeeding appear to be safe. The combination tablet is typically not appropriate for children.
It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. The wholesale cost in the developing world is about 8.54 to 18.94 USD a month as of 2014. The combination is not commercially available in the United States as of 2018.
- "Nevirapine, zidovudine and lamivudine" (PDF). aidsmap. Archived (PDF) from the original on 20 December 2016. Retrieved 18 December 2016.
- WHO Model Formulary 2008 (PDF). World Health Organization. 2009. pp. 157, 161. ISBN 9789241547659. Archived (PDF) from the original on 13 December 2016. Retrieved 8 December 2016.
- "WHO Model List of Essential Medicines (19th List)" (PDF). World Health Organization. April 2015. Archived (PDF) from the original on 13 December 2016. Retrieved 8 December 2016.
- "Lamivudine + Zidovudine + Nevirapine". International Drug Price Indicator Guide. Retrieved 8 December 2016.
- "Drugs@FDA: FDA Approved Drug Products". www.accessdata.fda.gov. Retrieved 6 January 2018.